# US 2026/0061066 A1 · Anti-grp78 antibody, immunoconjugate and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061066 A1
- Document ID: US20260061066A1
- Status: Published application
- Kind: A1
- Application number: 19/225,449
- Filed: 2025-06-02
- Published: 2026-03-05
- Earliest claimed: 2024-06-03
- Assignees: Uct Bioscience Co., Ltd.
- Applicants: Uct Bioscience Co., Ltd.
- Inventors: CHIA-CHENG WU; YA-WEI TSAI; CHIA-YING TSAI; CHIA-HSIANG LO
- Web page: https://patentgrep.com/patent/US20260061066A1

## CPC

- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/85: for animal cells
- G01N 2333/46: from vertebrates
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to an anti-glucose-related protein 78 (GRP78) antibody or an antigen-binding fragment thereof. The anti-GRP78 antibody or antigen-binding fragment thereof, such as a single chain variable fragment, can be used as an antigen binding domain of chimeric antigen receptors (CARs) or immunoconjugates for treating and/or preventing a disease and/or disorder caused by or related to GRP78 activity or signaling. The present disclosure also relates to a method or kit for detecting GRP78 or a cancer in a sample.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof that is specific to an epitope in glucose-related protein 78 (GRP78); wherein the isolated antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region and/or CDRs of a light chain variable region,
wherein the CDRs of the heavy chain variable region comprise:
CDRH1 having the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 1, CDRH2 having the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 2, and CDRH3 having the amino acid sequence of SEQ ID NO: 3 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 3; and
wherein the CDRs of the light chain variable region comprise:
CDRL1 having the amino acid sequence of SEQ ID NO: 4 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 4, CDRL2 having the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 5, and CDRL3 having the amino acid sequence of SEQ ID NO: 6 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 6.

### Claim 2 (depends on 1)

The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 7; or the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8 or the amino acid sequence with at least about 95% identity to SEQ ID NO: 8.

### Claim 3 (depends on 1)

The isolated antibody or antigen-binding fragment thereof of claim 1, which is an Fab fragment, an F(ab′) 2 fragment, an scFv fragment, a monoclonal antibody, a nanobody, a chimeric antibody, a composite antibody, a humanized antibody or a human antibody.

### Claim 4 (depends on 1)

The isolated antibody or antigen-binding fragment thereof of claim 1, which is expressed on a surface of a cell.

### Claim 5 (depends on 4)

The isolated antibody or antigen-binding fragment thereof of claim 4, wherein the cell is an immune cell or a stem cell.

### Claim 6 (depends on 1)

A genetically engineered cell expressing the isolated antibody or antigen-binding fragment thereof of claim 1.

### Claim 7 (depends on 6)

The genetically engineered cell of claim 6, which is an immune cell or a stem cell.

### Claim 8 (depends on 1)

An immunoconjugate that binds specifically to GRP78, comprising:
the isolated antibody or antigen-binding fragment thereof of claim 1, and
a therapeutic agent or a label,
wherein the immunoconjugate has the formula of
Ab-(L-D)m,
wherein Ab represents the isolated antibody or antigen-binding fragment thereof;
L represents a linker or a direct bond;
D represents the therapeutic agent or the label; and
m represents an integer from 1 to 15.

### Claim 9 (depends on 8)

The immunoconjugate thereof claim 8, wherein the linker is a hydrazone linker, a disulfide bond linker, a maleimidomethyl cyclohexane-1-carboxylate (MCC) linker, a maleimidocaproyl (MC) linker, a Val-Cit (valine-citrulline, VC) linker, a VC-PABC (valine-citrulline-p-aminobenzyl carbamate) linker, a GGFG (Gly-Gly-Phe-Gly) linker, an acid liable carbonate linker, or a sulfo-SPDB (N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate) linker.

### Claim 10 (depends on 8)

The immunoconjugate thereof claim 8, wherein the label is a radioisotope, a fluorescence, or a reporter enzyme.

### Claim 11 (depends on 8)

The immunoconjugate thereof claim 8, wherein the therapeutic agent is a calicheamicin, MMAE (monomethyl auristatin E), MMAF (monomethyl auristatin F), emtansine (DM1), ravtansine (DM4), pyrrolobenzodiazepine (PBD) dimer, exatecan, 7-ethyl-10-hydroxycamptothecin (SN38), or deruxtecan (Dxd).

### Claim 12 (depends on 8)

The immunoconjugate thereof claim 8, wherein the therapeutic agent is Dxd and the linker is VC, VC-PABC, or GGFG.

### Claim 13 (depends on 8)

The immunoconjugate thereof claim 8, wherein the linker is conjugated to the isolated antibody or antigen-binding fragment thereof through lysine-conjugation or cysteine-conjugation.

### Claim 14 (depends on 1)

A method for use in treating, prophylactically treating and/or preventing a disease and/or disorder caused by or related to GRP78 activity or signaling in a subject in need thereof, comprising administering the subject an effective amount of the isolated antibody or antigen-binding fragment thereof of claim 1 and optionally a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease is a cancer.

### Claim 16 (depends on 6)

A method for treating, prophylactically treating and/or preventing a disease and/or disorder caused by or related to GRP78 activity or signaling in a subject in need thereof, comprising administering the subject an effective amount of the genetically engineered cell of claim 6 and optionally a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disease is cancer.

### Claim 18 (depends on 8)

A method for treating, prophylactically treating and/or preventing a disease and/or disorder caused by or related to GRP78 activity or signaling in a subject in need thereof, comprising administering the subject an effective amount of the immunoconjugate of claim 8 and optionally a pharmaceutically acceptable carrier.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease is cancer.

### Claim 20 (depends on 1)

A method for detecting GRP78 or cancer in a sample, comprising contacting the sample with the isolated antibody or antigen-binding fragment thereof of claim 1.
